Skip to main content

Advertisement

SpringerLink
Log in

Effects of two diphosphonates (EHDP and Cl2MDP) on serum uric acid in pagetic patients

  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Summary

The effects on serum uric acid (SUA) of two diphosphonates (EHDP at 5 and 20 mg/kg/day and Cl2MDP at 400 and 1600 mg/day) were studied in 49 pagetic patients treated for 6 months. Patients were divided into two groups: group I, initially normouricemic (SUA <385µmol/l); group II, initially hyperuricemic (SUA ⩾385µmol/l). SUA was significantly decreased (P<0.01) after 6 months of diphosphonate therapy in all group II patients. However, 3 months after withdrawal of therapy, SUA returned to values not significantly different from those initially recorded in this group. SUA did not change during or after treatment in the group I patients. Groups I and II could not be differentiated on the basis of initial serum alkaline phosphatase or urinary hydroxyproline values. In response to therapy, both groups showed the same reduction in these parameters.

These results suggest that diphosphonates have no effect at a single level in uric acid metabolism. They certainly reduce the part of the urate pool coming from the nucleic acids of the increased bone cell population by reducing the number of osteoclasts and osteoblasts, which is extremely high in pagetic bone. They also must act on uric acid metabolism through other mechanisms which need to be investigated in further studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Russell, R. G. G., Smith, R., Preston, C., Walton, R. J., Woods, C. G.: Diphosphonates in Paget's disease, Lanceti:894–898, 1974

    Google Scholar 

  2. Frijlink, W. B., Bijvoet, O. L. M., Te Velde, J., Heynen, G.: Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1 biphosphonate (APD), Lanceti:799–803, 1979

    Article  Google Scholar 

  3. Meunier, P. J., Chapuy, M. C., Alexandre, C., Edouard, C., Bressot, C., Vignon, E., Mathieu, L., Trechsel, U.: Effects of disodium dichloromethylene diphosphonate (Cl2MDP) on Paget's disease of bone, Lancetii:489–492, 1979

    Article  Google Scholar 

  4. Franck, W. A., Bress, N. M., Singer, F. R., Krane, S. M.: Rheumatic manifestations of Paget's disease of bone, Am. J. Med.56:592–603, 1974

    Article  CAS  PubMed  Google Scholar 

  5. Liddle, L., Seegmiller, J. E., Laster, L.: The enzymatic spectrophotometric method for determination of uric acid, J. Lab. Clin. Med.54:903–913, 1959

    CAS  PubMed  Google Scholar 

  6. Klein, B., Read, P. A., Babson, A. L.: Rapid method for the quantitative determination of serum alkaline phosphatase, Clin. Chem.6:269, 1960

    CAS  PubMed  Google Scholar 

  7. Kivirikko, K. I., Laitinen, O., Prockop, D. J.: Modifications of a specific assay for hydroxyproline in urine, Anal. Biochem.19:249–255, 1967

    Article  CAS  PubMed  Google Scholar 

  8. Khairi, M. R. A., Johnston, C. C., Altman, R. D., Wellman, H. N., Serafini, A. N., Sankey, R. R.: Treatment of Paget's disease of bone (osteitis deformans). Results of one year study with sodium etidronate, J.A.M.A.230:562–567, 1974

    Article  CAS  PubMed  Google Scholar 

  9. Altman, R. D., Johnston, C. C., Khairi, M. R. A., Wellman, H., Serafini, A. N., Sankey, R. R.: Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans), N. Engl. J. Med.289:1379–1384, 1973

    Article  CAS  PubMed  Google Scholar 

  10. Meunier, P. J.: Disturbances in morphology and dynamics of the remodeling process in pagetic bone. In I. MacIntyre (ed.): Human Calcitonin and Paget's Disease, pp. 78–92. Hans Huber, Bern, 1977

    Google Scholar 

  11. Khairi, M. R. A., Meunier, P., Edouard, C., Courpron, P., Bernard, J., Derosa, G. P., Johnston, C. C.: Quantitative bone histology in Paget's disease of bone: influence of sodium etidronate (EHDP) therapy. In: Proceedings of the XIIth European Symposium on Calcified Tissues, York 1976, Calcif. Tissue Res. [Suppl.]22:355–358, 1977

    PubMed  Google Scholar 

  12. Khairi, M. R. A., Altman, R. D., Derosa, G. P., Zimmermann, J., Schenk, R. K., Johnston, C. C.: Sodium etidronate in the treatment of Paget's disease of bone. A study of long term results, Ann. Intern. Med.87:6, 656–663, 1977

    CAS  PubMed  Google Scholar 

  13. Seegmiller, M. E.: Diseases of purine and pyrimidine metabolism. In P. K. Bondy (ed.): Duncan's Diseases of Metabolism, 7th Ed., pp. 665–775. W. B. Saunders Co., Philadelphia, 1974

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. F.R.A. INSERM 44, Faculté Alexis Carrel, rue Paradin, 69008, Lyon

    Monique E. Arlot & Pierre J. Meunier

  2. Clinique de Rhumatologie, Pavillon E, Hôpital Edouard Herriot, 69003, Lyon, France

    Monique E. Arlot & Pierre J. Meunier

Authors
  1. Monique E. Arlot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pierre J. Meunier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arlot, M.E., Meunier, P.J. Effects of two diphosphonates (EHDP and Cl2MDP) on serum uric acid in pagetic patients. Calcif Tissue Int 33, 195–198 (1981). https://doi.org/10.1007/BF02409437

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02409437

Key words

Search

Navigation